Skip Navigation


Alcohol and Alcoholism Advance Access originally published online on November 5, 2007
Alcohol and Alcoholism 2008 43(1):70-72; doi:10.1093/alcalc/agm158
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/1/70    most recent
agm158v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Luykx, H. J.
Right arrow Articles by Hendriks, V. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luykx, H. J.
Right arrow Articles by Hendriks, V. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Copyright © The Author 2007. Published by Oxford University Press on behalf of the Medical Council on Alcohol.

Case Report

Rivastigmine in Wernicke-Korsakoff's syndrome: Five patients with rivastigmine showed no more improvement than five patients without rivastigmine

Han J. Luykx1,*, Lucille D. A. Dorresteijn2, P. M. Judith Haffmans3, Annette Bonebakker1, Margreet Kerkmeer1 and Vincent M. Hendriks4

1 Parnassia Groep, The Hague, The Netherlands
2 Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
3 Department of Research ParnassiaGroep, The Hague, The Netherlands
4 Parnassia Addiction Research Centre, The Hague, The Netherlands

* Author to whom correspondence should be addressed at: Parnassia-Medical Center, Jan Hein Donnerstraat 53, 2553 RZ The Hague, The Netherlands. Tel: (+003) 170 391 6900; Fax: (003) 170 391 6369; E-mail: luykxj{at}parnassia.nl

Received 26 October 2006; in revised form 1 December 2006; in revised form 6 July 2007; accepted 2 October 2007


  Abstract

Aims: To evaluate whether rivastigmine, an achetylcholinesterase inhibitor (AChEl), may be effective in restoring memory in Wernicke-Korsakoff's syndrome (WKS). Methods: Five patients treated with rivastigmine for a period of 6 months were compared with five matched control patients, who received 6 months' conventional treatment, but without rivastigmine. Memory tests were administered at baseline and after 6 months. Results: Slight improvements were observed in both rivastigmine and control patients, but no significant differences in improvements were found between the study groups. Conclusion: Treatment with rivastigmine may not be effective in restoring memory in WKS patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.